JW Therapeutics

About

JW Therapeutics (Hong Kong Stock Exchange: 2126) is a biotechnology company centered on innovation in cellular immunotherapy. The company was co-founded by WuXi AppTec and Juno Therapeutics in 2016, combining international cell-therapy R&D experience with local Chinese industrialization capabilities, and is committed to advancing the R&D, manufacturing and commercialization of cellular immunotherapy products, improving access to innovative treatments in China and global markets. We continuously build an integrated platform spanning academic discovery, process development, manufacturing, quality management and clinical application. Focused on hematologic malignancies, solid tumors and autoimmune diseases, we continue to advance a differentiated R&D pipeline and have established a system covering commercial-scale production and full-process quality management. Guided by the philosophy of 'curing the present with innovation, reshaping new life with vision,' JW Therapeutics is committed to bringing patients more high-quality cellular immunotherapy options, and bringing hope for cures to patients in China and around the world.